Similar companies
Related EMIS Industry Reports
The main business of Beijing Kangleweishi Biotechnology Co., Ltd. is the research and development of recombinant protein biological products based on structural design. The first series of products currently launched by the company based on structural design are human papillomavirus (HPV) vaccines. The first product in the series of HPV vaccines is the recombinant trivalent human papillomavirus (type 16/18/58) vaccine (E. coli). On January 2, 2018, the company obtained the "Drug Registration Application Acceptance Notice" for the clinical trial of "Recombinant nine-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (E. coli)" Book".
Headquarters
Rooms 201 and 202, Building A2, Longsheng Industrial Park, No. 7 Rongchang East Street, Beijing Economic and Technological Development Zone
Beijing; Beijing;
Postal Code: 100176
Contact Details: Purchase the Beijing Health Guard Biotechnology Inc. report to view the information.
Website: http://www.klws.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service